Share on StockTwits

HeartWare International (NASDAQ:HTWR) was downgraded by Zacks from an “outperform” rating to a “neutral” rating in a research report issued to clients and investors on Monday. They currently have a $95.10 price objective on the stock. Zacks‘s price objective indicates a potential upside of 17.26% from the stock’s previous close.

HTWR has been the subject of a number of other recent research reports. Analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of HeartWare International in a research note on Friday, August 1st. They now have a $125.00 price target on the stock, down previously from $128.00. Analysts at Leerink Swann cut their price target on shares of HeartWare International from $120.00 to $105.00 in a research note on Friday, August 1st. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company. HeartWare International has an average rating of “Buy” and an average price target of $107.91.

HeartWare International (NASDAQ:HTWR) traded up 0.90% during mid-day trading on Monday, hitting $81.10. 115,874 shares of the company’s stock traded hands. HeartWare International has a 1-year low of $69.31 and a 1-year high of $105.84. The stock’s 50-day moving average is $84.15 and its 200-day moving average is $89.56. The company’s market cap is $1.379 billion.

HeartWare International (NASDAQ:HTWR) last released its earnings data on Thursday, July 31st. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.74) by $0.45. The company had revenue of $70.10 million for the quarter, compared to the consensus estimate of $67.01 million. On average, analysts predict that HeartWare International will post $-2.20 earnings per share for the current fiscal year.

In other HeartWare International news, Insider Jeffrey Larose sold 2,179 shares of HeartWare International stock on the open market in a transaction dated Tuesday, August 19th. The shares were sold at an average price of $81.51, for a total value of $177,610.29. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Heartware International, Inc (NASDAQ:HTWR) develops and manufactures small implantable heart pumps, or ventricular assist devices, for the treatment of advanced heart failure.

To view Zacks’ full report, visit Zacks’ official website.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.